An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy

Abstract Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized N...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Marta Rodríguez, Ruth Alonso‐Alonso, Ismael Fernández‐Miranda, Rufino Mondéjar, Laura Cereceda, Álvaro Tráscasa, Anabel Antonio‐Da Conceiçao, Jennifer Borregón, Lucía Gato, Laura Tomás‐Roca, Carmen Bárcena, Begoña Iglesias, Fina Climent, Eva González‐Barca, Francisca Inmaculada Camacho, Émpar Mayordomo, Gabriel Olmedilla, Pilar Gómez‐Prieto, Yolanda Castro, Juana Serrano‐López, Joaquín Sánchez‐García, Santiago Montes‐Moreno, Mónica García‐Cosío, Paloma Martín‐Acosta, Juan F. García, María Planelles, Cristina Quero, Mariano Provencio, Ignacio Mahíllo‐Fernández, Socorro M. Rodríguez‐Pinilla, Enrico Derenzini, Stefano Pileri, Margarita Sánchez‐Beato, Raúl Córdoba, Miguel A. Piris
Materialtyp: Artikel
Språk:English
Publicerad: Wiley 2022-08-01
Serie:eJHaem
Ämnen:
DLBCL
gene expression
immunochemotherapy
diffuse large B‐cell lymphoma
prognosis
Länkar:https://doi.org/10.1002/jha2.457

Internet

https://doi.org/10.1002/jha2.457

Liknande verk